MedTrace Logo

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

NCT04637763 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-03-24

No results posted yet for this study

Summary

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.

Conditions

  • Lymphoma, Non-Hodgkin
  • Relapsed Non Hodgkin Lymphoma
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • Non Hodgkin Lymphoma
  • Lymphoma
  • B Cell Lymphoma
  • B Cell Non-Hodgkin's Lymphoma

Interventions

GENETIC

CB-010

CB-010 is a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19.

DRUG

Cyclophosphamide

Chemotherapy for lymphodepletion

DRUG

Fludarabine

Chemotherapy for lymphodepletion

Sponsors & Collaborators

  • Caribou Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-26
Primary Completion
2025-08-31
Completion
2025-09-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Israel

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04637763 on ClinicalTrials.gov